A Phase I dose‐escalation study of two cycles carboplatin‐olaparib followed by olaparib monotherapy in patients with advanced cancer

Preclinical studies have shown synergistic effects when combining PARP1/2 inhibitors and platinum drugs in BRCA1/2 mutated cancer cell models. After a formulation change of olaparib from capsules to tablets, we initiated a dose finding study of olaparib tablets bidaily (BID) continuously with carbop...

Descripción completa

Detalles Bibliográficos
Autores principales: Geenen, Jill J. J., Dackus, Gwen M. H. E., Schouten, Philip C., Pluim, Dick, Marchetti, Serena, Sonke, Gabe S., Jóźwiak, Katarzyna, Huitema, Alwin D. R., Beijnen, Jos H., Schellens, Jan H. M., Linn, Sabine C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248128/
https://www.ncbi.nlm.nih.gov/pubmed/33539540
http://dx.doi.org/10.1002/ijc.33498

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248128/
https://www.ncbi.nlm.nih.gov/pubmed/33539540
http://dx.doi.org/10.1002/ijc.33498

Ejemplares similares